Recently, the phase II study of lorlatinib has been reported.11, 29 The cohort with at least one secondary mutation in the baseline tumor biopsy had a PFS of 11.0 months, while the cohort with no secondary mutation in the baseline biopsy had a PFS of 5.4 months.29 This result suggests that the PFS in the current study was relatively short; however, the previous cohorts included patients treated with not only second‐generation ALK‐TKIs, but also crizotinib as pretreatment of lorlatinib. Here, ALK is linked to neoplasm.